You are here

Virginia Kraus

Professor of Medicine, Professor of Pathology, Associate Professor of Surgery
Pathology
919-681-6652
Research Interest: 
Genetics
Immunology
Molecular structure
Research Summary: 
Pathogenesis of arthritis and development of novel biomarker tools to aid in the diagnosis, prognosis, monitoring, and effective intervention of the disease in humans and animal model systems.
Research Description: 

A major focus of this laboratory is on the role of inflammatory mediators and proteases in the pathogenesis of osteoarthritis and the influence of genotype on its phenotypic manifestations. This lab actively develops and validates surrogate biomarkers to advance the practice of clinical diagnosis and prognosis of the disease. The laboratory has ongoing basic research projects involving in vitro and animal model systems in spontaneous and injury associated arthritis, as well as biomedical clinical research trials in osteoarthritis in man. The lab has ongoing proteomic analyses of joint fluid and joint tissues to identify potential new biomarkers of OA progression and to understand the differences in joint tissue metabolism in different joints.

Publications: 
Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation.
Denoble AE, Huffman KM, Stabler TV, Kelly SJ, Hershfield MS, McDaniel GE, Coleman RE, Kraus VB.
Proc Natl Acad Sci U S A. 2011. 108:2088-93.

Protein modification by deamidation indicates variations in joint extracellular matrix turnover.
Catterall JB, Hsueh MF, Stabler TV, McCudden CR, Bolognesi M, Zura R, Jordan JM, Renner JB, Feng S, Kraus VB.
J Biol Chem. 2012. 287:4640-51.

Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254).
Catterall JB, Stabler TV, Flannery CR, Kraus VB.
Arthritis Res Ther. 2010. 12:R229.

First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis.
Kraus VB, Kepler TB, Stabler T, Renner J, Jordan J.
PLoS One. 2010. 5:e9739.

Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation.
Addison S, Coleman RE, Feng S, McDaniel G, Kraus VB.
Arthritis Rheum. 2009. 60:3366-73.